Aligos Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ALGS Nasdaq 2836 www.aligos.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aligos Therapeutics, Inc.

Here’s Why Aligos Therapeutics, Inc. (ALGS) Is Skyrocketing - Jan 13th, 2025 9:32 pm
Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) biggest owners are retail investors who got richer after stock soared 17% last week - Dec 21st, 2024 1:43 pm
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 13th, 2024 1:00 pm
Aligos Therapeutics to Present at Investor Conferences in December - Nov 26th, 2024 1:00 pm
Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024 - Nov 19th, 2024 6:30 pm
Aligos Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations - Nov 10th, 2024 12:51 pm
Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates - Nov 6th, 2024 11:05 pm
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results - Nov 6th, 2024 9:05 pm
Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024 - Oct 30th, 2024 8:05 pm
Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184 - Oct 22nd, 2024 12:00 pm
Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024 - Oct 15th, 2024 1:00 pm
Aligos Therapeutics Appoints David Perry as Vice President of Business Development - Oct 1st, 2024 12:00 pm
Aligos Therapeutics to Present at Investor Conferences in October - Sep 30th, 2024 12:00 pm
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer - Sep 24th, 2024 12:00 pm
Aligos reports positive data from Phase IIa MASH treatment trial - Sep 20th, 2024 8:52 am
Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH - Sep 19th, 2024 12:00 pm
Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024 - Sep 18th, 2024 9:00 pm
Are Medical Stocks Lagging Aligos Therapeutics (ALGS) This Year? - Sep 10th, 2024 1:40 pm
How Much Upside is Left in Aligos Therapeutics (ALGS)? Wall Street Analysts Think 648.14% - Aug 21st, 2024 1:55 pm
Aligos Therapeutics Announces Reverse Stock Split - Aug 15th, 2024 1:00 pm